tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Apr 19;10(5)
fad205.
doi: 10.1093/ofid/ofad205. eCollection 2023 May. Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Daniel A Sweeney[SUP] 1 [/SUP], Bonifride Tuyishimire[SUP] 2 [/SUP], Neera Ahuja[SUP] 3 [/SUP], John H Beigel[SUP] 4 [/SUP], Tatiana Beresnev[SUP] 4 [/SUP], Valeria D Cantos[SUP] 5 [/SUP], Jose G Castro[SUP] 6 [/SUP], Stuart H Cohen[SUP] 7 [/SUP], Kaitlyn Cross[SUP] 2 [/SUP], Lori E Dodd[SUP] 4 [/SUP], Nathan Erdmann[SUP] 8 [/SUP], Monica Fung[SUP] 9 [/SUP], Varduhi Ghazaryan[SUP] 4 [/SUP], Sarah L George[SUP] 10 [/SUP], Kevin A Grimes[SUP] 11 [/SUP], Noreen A Hynes[SUP] 12 [/SUP], Kathleen G Julian[SUP] 13 [/SUP], Sheetal Kandiah[SUP] 5 [/SUP], Hannah Jang Kim[SUP] 14 15 [/SUP], Corri B Levine[SUP] 16 [/SUP], David A Lindholm[SUP] 17 18 [/SUP], David C Lye[SUP] 19 20 21 22 [/SUP], Ryan C Maves[SUP] 23 [/SUP], Myoung-Don Oh[SUP] 24 [/SUP], Catharine Paules[SUP] 13 [/SUP], Rekha R Rapaka[SUP] 25 [/SUP], Willam R Short[SUP] 26 [/SUP], Kay M Tomashek[SUP] 4 [/SUP], Cameron R Wolfe[SUP] 27 [/SUP], Andre C Kalil[SUP] 28 [/SUP]
Affiliations
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
Keywords: COVID-19; baricitinib; secondary infections.
. 2023 Apr 19;10(5)
fad205.doi: 10.1093/ofid/ofad205. eCollection 2023 May. Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Daniel A Sweeney[SUP] 1 [/SUP], Bonifride Tuyishimire[SUP] 2 [/SUP], Neera Ahuja[SUP] 3 [/SUP], John H Beigel[SUP] 4 [/SUP], Tatiana Beresnev[SUP] 4 [/SUP], Valeria D Cantos[SUP] 5 [/SUP], Jose G Castro[SUP] 6 [/SUP], Stuart H Cohen[SUP] 7 [/SUP], Kaitlyn Cross[SUP] 2 [/SUP], Lori E Dodd[SUP] 4 [/SUP], Nathan Erdmann[SUP] 8 [/SUP], Monica Fung[SUP] 9 [/SUP], Varduhi Ghazaryan[SUP] 4 [/SUP], Sarah L George[SUP] 10 [/SUP], Kevin A Grimes[SUP] 11 [/SUP], Noreen A Hynes[SUP] 12 [/SUP], Kathleen G Julian[SUP] 13 [/SUP], Sheetal Kandiah[SUP] 5 [/SUP], Hannah Jang Kim[SUP] 14 15 [/SUP], Corri B Levine[SUP] 16 [/SUP], David A Lindholm[SUP] 17 18 [/SUP], David C Lye[SUP] 19 20 21 22 [/SUP], Ryan C Maves[SUP] 23 [/SUP], Myoung-Don Oh[SUP] 24 [/SUP], Catharine Paules[SUP] 13 [/SUP], Rekha R Rapaka[SUP] 25 [/SUP], Willam R Short[SUP] 26 [/SUP], Kay M Tomashek[SUP] 4 [/SUP], Cameron R Wolfe[SUP] 27 [/SUP], Andre C Kalil[SUP] 28 [/SUP]
Affiliations
- PMID: 37206623
- PMCID: PMC10191442
- DOI: 10.1093/ofid/ofad205
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
Keywords: COVID-19; baricitinib; secondary infections.